<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02988466</url>
  </required_header>
  <id_info>
    <org_study_id>2016LS092</org_study_id>
    <secondary_id>MT2016-15</secondary_id>
    <nct_id>NCT02988466</nct_id>
  </id_info>
  <brief_title>Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haploidentical Related Hematopoietic</brief_title>
  <official_title>Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haploidentical Related Hematopoietic Cells (Haplo-HCT) For Patients With Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single institution phase II study of a reduced intensity conditioning (RIC)
      followed by a haploidentical hematopoietic cell transplant (haplo-HCT) in persons with
      diagnosis of hematologic malignancy. Conditioning will consists of fludarabine,
      cyclophosphamide, melphalan and total body irradiation (TBI) preparative regimen with a
      melphalan dose reduction for patients ≥55 years old and those with HCT Comorbidity Index (CI)
      &gt;3. This study uses a two-stage phase II design with accrual goal of 44 patients, using 22
      patients separately for arms A and B.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 24, 2017</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival (DFS)</measure>
    <time_frame>1 year</time_frame>
    <description>estimate disease-free survival (DFS) at 1 year post-transplant</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of grade II-IV and grade III-IV acute graft versus-host-disease (GVHD)</measure>
    <time_frame>day 100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment related mortality (TRM)</measure>
    <time_frame>6 month, 1 and 2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse incidence</measure>
    <time_frame>1 and 2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of serious fungal and viral infection</measure>
    <time_frame>at day 100 and 1 year</time_frame>
    <description>post-HCT</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Hematologic Malignancies</condition>
  <arm_group>
    <arm_group_label>Arm A: Haplo-HCT &lt;55 years old</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Reduced-intensity conditioning and transplantation of human leukocyte antigen (HLA) -haploidentical related donor stem cells for patients &lt;55 years old with hematopoietic cell transplantation Comorbidity Index (HCT-CI) ≤2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Haplo-HCT ≥55 years old</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Reduced-intensity conditioning and transplantation of human leukocyte antigen (HLA) -haploidentical related donor stem cells for patients ≥55 years old or younger with hematopoietic cell transplantation Comorbidity Index (HCT-CI) ≥3.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Haplo HCT &lt;55 years old</intervention_name>
    <description>Fludarabine (Flu)
Cyclophosphamide (Cy)
Melphalan (Mel)
Total body irradiation (TBI)
Non-T-cell depleted donor bone marrow stem cell infusion Day 0</description>
    <arm_group_label>Arm A: Haplo-HCT &lt;55 years old</arm_group_label>
    <other_name>HLA-haploidentical related hematopoietic cells transplant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Haplo HCT ≥55 years old</intervention_name>
    <description>Fludarabine (Flu)
Cyclophosphamide (Cy)
Melphalan (Mel): Dose reduction by 30%
Total body irradiation (TBI)
Non-T-cell depleted donor bone marrow stem cell infusion</description>
    <arm_group_label>Arm B: Haplo-HCT ≥55 years old</arm_group_label>
    <other_name>HLA-haploidentical related hematopoietic cells transplant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GVHD Prophylaxis</intervention_name>
    <description>Cyclophosphamide (Cy)
Tacrolimus (Tac)
Mycophenolate mofetil (MMF)</description>
    <arm_group_label>Arm A: Haplo-HCT &lt;55 years old</arm_group_label>
    <arm_group_label>Arm B: Haplo-HCT ≥55 years old</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Karnofsky performance status of ≥70% or Lansky play score ≥ 70%

          -  A related haploidentical bone marrow donor with up to 2 or 3 HLA locus-mismatches

          -  The donor and recipient must be HLA identical for at least one haplotype (using high
             resolution DNA based typing) at the following genetic loci: HLA-A, HLA-B, HLA-C, and
             HLA-DRB1.

          -  Adequate liver and renal function

          -  Absence of decompensated congestive heart failure, or uncontrolled arrhythmia and left
             ventricular ejection fraction ≥ 40%

          -  Diffusion capacity corrected (DLCOcorr) &gt; 40% predicted, and absence of O2
             requirements

          -  &gt; 6 months after prior autologous transplant (if applicable)

          -  Agrees to use contraception during study treatment

          -  Voluntary written consent (adult or parent/guardian with presentation of the minor
             information sheet, if appropriate)

        Exclusion Criteria:

          -  &lt; 70 years with an available 5-6/6 HLA-A, B, DRB1 matched sibling donor

          -  Pregnancy or breastfeeding

          -  Evidence of HIV infection or known HIV positive serology

          -  Current active and uncontrolled serious infection

          -  Acute leukemia in morphologic relapse/persistent disease defined as &gt; 5% blasts in
             normocellular bone marrow OR any % blasts if blasts have unique morphologic markers
             (e.g. Auer rods).

          -  CML in blast crisis

          -  Large cell lymphoma, mantle cell lymphoma and Hodgkin disease that is progressive on
             salvage therapy.

          -  stable non-bulky disease is acceptable.

          -  Active central nervous system malignancy

        Criteria For Donor Selection:

          -  Donors must be HLA-haploidentical relatives of the patient, defined as having a shared
             HLA haplotype between donor and patient at HLA-A, -B, -C, and -DRB1.

          -  Eligible donors (14-70 years old) include biological children, siblings or half
             siblings, or parents, able and willing to undergo bone marrow harvesting.

          -  For donors &lt;18 years, the maximum recipient weight (actual body weight) should not
             exceed 1.25 times the donor weight (actual body weight)1 In addition, bone marrow
             product volume should be limited to 20 ml/kg donor weight for donors &lt;18 years.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nelli Bejanyan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Masonic Cancer Center, University of Minnesota</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Timothy Krepski</last_name>
    <phone>612-273-2800</phone>
    <email>tkrepsk1@fairview.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Masonic Cancer Center at University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tim Krepski</last_name>
      <phone>612-273-2800</phone>
      <email>tkrepsk1@fairview.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 7, 2016</study_first_submitted>
  <study_first_submitted_qc>December 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2016</study_first_posted>
  <last_update_submitted>December 3, 2017</last_update_submitted>
  <last_update_submitted_qc>December 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Leukemias</keyword>
  <keyword>Acute myeloid leukemia (AML)</keyword>
  <keyword>Acute lymphoblastic leukemia (ALL)/lymphoma</keyword>
  <keyword>Biphenotypic/Undifferentiated/Prolymphocytic Leukemias</keyword>
  <keyword>Myelodysplastic syndrome</keyword>
  <keyword>Chronic myelogenous leukemia</keyword>
  <keyword>Minimal Residual Disease (MRD) positive leukemia</keyword>
  <keyword>Leukemia or Myelodysplastic Syndromes (MDS) in aplasia</keyword>
  <keyword>Myeloproliferative neoplasms/myelofibrosis</keyword>
  <keyword>Relapsed large-cell lymphoma, mantle-cell lymphoma and Hodgkin lymphoma</keyword>
  <keyword>Burkitt's lymphoma</keyword>
  <keyword>Relapsed T-cell lymphoma</keyword>
  <keyword>Natural Killer cell malignancies</keyword>
  <keyword>Relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), marginal zone B-cell lymphoma, follicular lymphoma</keyword>
  <keyword>Lymphoplasmacytic lymphoma</keyword>
  <keyword>Relapsed multiple myeloma</keyword>
  <keyword>Bone marrow failure syndromes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

